The key to immunotherapy: how to choose better therapeutic biomarkers for patients with non-small cell lung cancer

Yue Pan; Yucheng Fu; Yue Zeng; Xiaohan Liu; Yurong Peng; Chunhong Hu; Chao Deng; Zhenhua Qiu; Jian Zou; Yuxuan Liu; Fang Wu

doi:10.1186/s40364-022-00355-7

The key to immunotherapy: how to choose better therapeutic biomarkers for patients with non-small cell lung cancer

Biomark Res. 2022 Mar 7;10(1):9. doi: 10.1186/s40364-022-00355-7.

Authors

Yue Pan¹, Yucheng Fu², Yue Zeng¹, Xiaohan Liu¹, Yurong Peng¹, Chunhong Hu¹, Chao Deng¹, Zhenhua Qiu¹, Jian Zou³, Yuxuan Liu³, Fang Wu^{4

5

6

7}

Affiliations

¹ Department of Oncology, The Second Xiangya Hospital, Central South University, Changsha, 410011, Hunan, China.
² Hunan University of Chinese Medicine, Changsha, 410208, Hunan, People's Republic of China.
³ Xiangya School of Medicine, Central South University, Changsha, 410013, Hunan, People's Republic of China.
⁴ Department of Oncology, The Second Xiangya Hospital, Central South University, Changsha, 410011, Hunan, China. wufang4461@csu.edu.cn.
⁵ Hunan Cancer Mega-Data Intelligent Application and Engineering Research Centre, Hunan, China. wufang4461@csu.edu.cn.
⁶ Hunan Key Laboratory of Tumor Models and Individualized Medicine, The Second Xiangya Hospital, Central South University, Changsha, 410011, Hunan, China. wufang4461@csu.edu.cn.
⁷ Hunan Key Laboratory of Early Diagnosis and Precision Therapy in Lung Cancer, The Second Xiangya Hospital, Central South University, Changsha, 410011, Hunan, China. wufang4461@csu.edu.cn.

Abstract

Immunotherapy has become the standard of care for non-small cell lung cancer (NSCLC), either in combination or monotherapy. However, there are still some patients who cannot benefit from it. Immunization strategies for NSCLC are based on the expression of PD-L1 on tumor cells and TMB, and although these indicators have a certain predictive effect, their predictive performance is not good. Therefore, clinicians must make adjustments to recognize markers. This is a review article that summarized immunotherapeutic biomarkers according to the "seed-soil-environment", generalizes primary resistance to immunotherapy, and summarizes the integration of markers.

Keywords: Biomarkers; Immune checkpoint inhibitors; NSCLC; PD-L1.

Publication types

Review

Abstract

Publication types

Grants and funding